Neuroendocrine Tumors Pipeline Insight

DelveInsight’s, “Neuroendocrine Tumors Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Neuroendocrine Tumors Understanding

Neuroendocrine Tumors Overview

Neuroendocrine tumors (NETs), also referred to as neuroendocrine neoplasms, are a heterogeneous group of malignancies that arise from neuroendocrine cells possessing both neural and hormone-secreting functions. These cells are distributed throughout the body, particularly in the gastrointestinal tract, lungs, and pancreas, making the clinical presentation of NETs highly variable. Most NETs are slow-growing and indolent, although certain subtypes may behave aggressively and progress rapidly. Early-stage disease is frequently asymptomatic or associated with nonspecific symptoms, leading to incidental diagnosis during imaging or evaluation for unrelated conditions. Clinical manifestations may result from tumor burden or excess hormone secretion and can include abdominal pain, diarrhea, flushing, cough, fatigue, weight loss, jaundice, and metabolic abnormalities such as hyperglycemia or hypoglycemia, often contributing to delayed diagnosis and treatment.

Neuroendocrine tumors (NETs) are malignancies arising from hormone-secreting neuroendocrine cells found in multiple organs. Their pathophysiology is driven by abnormal hormone production and dysregulated signaling pathways that promote tumor growth and survival. Disease behavior varies widely, with well-differentiated NETs typically progressing slowly, while poorly differentiated forms are more aggressive. Key molecular mechanisms involve alterations in the PI3K/Akt/mTOR, Notch, and Wnt pathways. Genetic and epigenetic changes further contribute to tumor development, progression, and treatment variability.

The diagnosis of neuroendocrine tumors (NETs) requires a multidisciplinary approach integrating clinical assessment, imaging studies, laboratory investigations, and pathological evaluation. Although many NETs are discovered incidentally, suspected cases are typically evaluated through detailed medical history, physical examination, and tissue biopsy to confirm the diagnosis. Blood and urine analyses are commonly used to detect hormone levels and tumor-associated biomarkers. Imaging modalities such as CT, MRI, endoscopy, and PET scans play an important role in identifying tumor location, extent, and disease stage. In some cases, molecular profiling and biomarker testing may further assist therapeutic decision-making, though their application in NETs remains relatively limited.

The treatment of neuroendocrine tumors (NETs) requires a multidisciplinary and individualized approach based on tumor site, stage, grade, hormonal activity, and overall patient condition. Active surveillance may be considered for indolent, slow-growing tumors, while surgical resection remains the preferred option for localized disease. In advanced cases, debulking procedures may help reduce tumor burden and control symptoms when complete removal is not possible. Systemic treatment options include somatostatin analogs, targeted therapies, chemotherapy, immunotherapy, and peptide receptor radionuclide therapy depending on tumor biology and progression. Supportive and symptom-directed management also plays an important role in improving patient outcomes and quality of life.

"Neuroendocrine Tumors Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neuroendocrine Tumors pipeline landscape is provided which includes the disease overview and Neuroendocrine Tumors treatment guidelines. The assessment part of the report embraces, in depth Neuroendocrine Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuroendocrine Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Neuroendocrine Tumors Pipelin Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Neuroendocrine Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Neuroendocrine Tumors.

Neuroendocrine Tumors Emerging Drugs Analysis

This segment of the Neuroendocrine Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neuroendocrine Tumors Emerging Drugs

Obrixtamig: Boehringer Ingelheim

Obrixtamig (BI 764532) is an investigational bispecific T-cell engager designed for the treatment of neuroendocrine tumors, including DLL3-positive malignancies such as small cell lung carcinoma. The therapy simultaneously binds delta-like ligand 3 (DLL3) expressed on tumor cells and CD3 receptors on T cells, thereby redirecting immune-mediated cytotoxicity toward cancer cells. DLL3 is highly overexpressed in several neuroendocrine cancers while showing limited expression in normal tissues, supporting its potential as a selective therapeutic target. Obrixtamig is currently being investigated in a Phase III clinical trial for patients with neuroendocrine tumors.

ZG006: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

ZG006 (alveltamig) is an investigational trispecific T-cell engager developed to target two distinct epitopes of delta-like ligand 3 (DLL3) on tumor cells and CD3 on T cells, thereby redirecting immune cells to selectively eliminate DLL3-expressing cancer cells. DLL3 is highly expressed in neuroendocrine carcinomas and small cell lung cancer while showing minimal expression in normal tissues, supporting a targeted therapeutic strategy. ZG006 is currently in Phase III stage of its development.

Zanzalintinib: Exelixis

Zanzalintinib (XL092) is an investigational oral tyrosine kinase inhibitor developed by Exelixis that targets multiple pathways involved in tumor growth, angiogenesis, and metastasis, including VEGFR, MET, and TAM kinases. The therapy is being evaluated for patients with previously treated, unresectable, locally advanced, or metastatic pancreatic and extra-pancreatic neuroendocrine tumors. Zanzalintinib is currently under investigation in the Phase II/III STELLAR-311 clinical trial comparing its efficacy and safety with everolimus in advanced NET patients.

CVM-1118: TaiRx, Inc

CVM-1118 (also known as TRX-818 or foslinanib) is an investigational oral small-molecule anticancer therapy being developed by TaiRx, Inc. for advanced neuroendocrine tumors (NETs). The agent has demonstrated antitumor activity across multiple cancer cell lines and is believed to inhibit vasculogenic mimicry, a mechanism associated with tumor vascularization and progression in NETs. It is currently being evaluated in an open-label Phase II study in patients with unresectable or metastatic, well-differentiated NETs of pancreatic, gastrointestinal, or lung origin that are refractory to standard therapies. The trial is assessing endpoints including progression-free survival, objective response rate, safety, and pharmacokinetics of oral CVM-1118 administered twice daily.

CRN09682: Crinetics Pharmaceuticals Inc.

CRN09682 is an investigational nonpeptide drug conjugate being developed by Crinetics Pharmaceuticals for patients with SST2-positive neuroendocrine neoplasms and other solid tumors. The therapy selectively binds to SST2-expressing tumor cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE) intracellularly following receptor internalization, aiming to enhance antitumor activity while limiting systemic toxicity. CRN09682 is currently being evaluated in the Phase I/II BRAVESST2 clinical trial in patients with progressive metastatic or locally advanced SST2-expressing neuroendocrine tumors and related malignancies.

ML261: Moonlight Bio, Inc

ML261 is an investigational autologous anti-DLL3 CAR T-cell therapy being developed for relapsed or refractory small cell lung cancer and selected neuroendocrine carcinomas expressing delta-like ligand 3 (DLL3). The therapy incorporates a potency-enhanced CAR T-cell platform with a CARD11-PIK3R3 fusion construct designed to improve T-cell activation, persistence, and antitumor activity against DLL3-positive tumor cells. ML261 is currently being evaluated in the first-in-human Phase I SPECTRAL-1 study to assess its safety, pharmacokinetics, and preliminary efficacy in patients with advanced neuroendocrine malignancies.

Further product details are provided in the report……..

Neuroendocrine Tumor Drug Therapeutic Assessment

This segment of the report provides insights about the different Neuroendocrine Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Neuroendocrine Tumors Players in Neuroendocrine Tumors

There are approx. 80+ key companies which are developing the therapies for Neuroendocrine Tumors. The companies which have their Neuroendocrine Tumors drug candidates in the most advanced stage, i.e. Phase III include, Boehringer Ingelheim.

Neuroendocrine Tumors Clinical Trial Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Neuroendocrine Tumors Drug Route of Administration

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Neuroendocrine Tumors Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Neuroendocrine Tumors Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neuroendocrine Tumors Clinical Trial Activities

The Neuroendocrine Tumors Pipeline report provides insights into different Neuroendocrine Tumors Clinical Trial within Phase III, II, I, preclinical and discovery stage. It also analyses Neuroendocrine Tumors therapeutic drugs key players involved in developing key drugs. 

Neuroendocrine Tumors Pipeline Development Activities

The Neuroendocrine Tumors Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuroendocrine Tumors drugs.

Neuroendocrine Tumors Report Insights

• Neuroendocrine Tumors Pipeline Analysis
• Neuroendocrine Tumors Therapeutic Assessment
• Neuroendocrine Tumors Unmet Needs
• Impact of Neuroendocrine Tumors Drugs

Neuroendocrine Tumors Report Assessment

• Neuroendocrine Tumors Pipeline Product Profiles
• Neuroendocrine Tumors Therapeutic Assessment
• Neuroendocrine Tumors Pipeline Assessment
• Neuroendocrine Tumors Inactive drugs assessment
• Neuroendocrine Tumors Market Unmet Needs

Key Questions Answered In the Neuroendocrine Tumors Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Neuroendocrine Tumors drugs?
• How many Neuroendocrine Tumors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neuroendocrine Tumors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neuroendocrine Tumors therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Neuroendocrine Tumors and their status?
• What are the key designations that have been granted to the emerging drugs?

Neuroendocrine Tumors Key Players

• Boehringer Ingelheim
• Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• Exelixis
• Crinetics Pharmaceuticals Inc.
• Seneca Therapeutics
• Moonlight Bio, Inc
• Chimeric Therapeutics
• RayzeBio, Inc.
• Camurus
• Legend Biotech
• Phanes Therapeutics
• Hansoh BioMedical R&D Company
• BioNTech
• Sichuan Baili Pharmaceutical Co., Ltd.
• IDEAYA Biosciences
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
• Novelty Nobility, Inc.
• Hangzhou DAC Biotechnology Co., Ltd.
• Recursion Pharmaceuticals
• Shanghai Henlius Biotech
• TaiRx, Inc.
• Abdera Therapeutics
• Legend Biotech

Neuroendocrine TumorsKey Products

• Obrixtamig
• ZG006
• Zanzalintinib
• CRN09682
• SVV-001
• ML261
• CHM-2101
• RYZ101
• CAM2029
• LB2102
• PT217
• HS-20108
• BNT326
• BL-M14D1
• IDE849
• FZ-AD005
• NN3201
• DXC014
• EXS74539
• HLX3901
• CVM-1118
• ABD 147
• LB2102